Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma –results from the UK MRC OE02 trial

Hale, MD, Nankivell, M, Hutchins, GG et al. (11 more authors) (2016) Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma –results from the UK MRC OE02 trial. Oncotarget, 7 (47). pp. 77565-77575. ISSN 1949-2553

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016, The Author(s). This article is licensed under a Creative Commons Attribution 3.0 License.
Keywords: oesophageal cancer; proportion of tumour; neoadjuvant chemotherapy; biomarker; tumour stroma
Dates:
  • Accepted: 30 September 2016
  • Published (online): 18 October 2016
  • Published: 22 November 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Funding Information:
FunderGrant number
Cancer Research UKC26441/A8944
Yorkshire Cancer ResearchL386
Depositing User: Symplectic Publications
Date Deposited: 10 Oct 2016 10:46
Last Modified: 05 Oct 2017 16:22
Published Version: http://dx.doi.org/10.18632/oncotarget.12723
Status: Published
Publisher: Impact Journals
Identification Number: https://doi.org/10.18632/oncotarget.12723

Share / Export

Statistics